Imagine a world where genetic diseases are treated with orally-available small molecule drugs.  That's the future Sharp Edge Labs is building.  Sharp Edge is a preclinical-stage life sciences company developing drugs for genetic diseases.   Our monogenic disease focus de-risks the clinical path. Each pipeline program has a genetically identifiable subset of patients and an early Phase IB pharmacodynamic readout.  

We combine three core techologies to create a scalable platform for discovery and development.  CoreX(tm) is s suite of assay technologies that enable the creation of realistic cellular models of genetic diseases.  AlloChem(tm) is a proprietary compound library computationally biased to contain molecules that can bind proteins allosterically, stabilizing them, and restoring their function.  Disco/Mine(tm) is a suite of computational and machine learning tools that enhances our experimental approach rather than replacing it.  These combine to create a scalable platform with over 10 programs at various stages of development.
The company has programs in Frontotemporal Dementia, and genetic subsets of Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders and other loss-of-function diseases.
 The team and its advisors includes ex and current Genzyme/Sanofi, Synageva, Pfizer and Shire executives.

Sharp Therapeutics

Org chart

Teams

Offices